Therapeutic Asset Ratings

119 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cobolimab Neoplasms	GlaxoSmithKline	P1	CC (44)
Enzalutamide Neoplasms	GlaxoSmithKline	P1	CC (44)
DARATUMUMAB Neoplasms	Hellenic Society of Hematology	P1/2	CC (44)
rd13-02 cell infusion Neoplasms	Kai Lin Xu，MD	Early P1	CC (41)
Acit-1 Neoplasms	Cancer Vaccines Limited	P1/2	CC (41)
Elacestrant Neoplasms	Stemline Therapeutics, Inc.	P1/2	CC (41)
gsk2857916 Neoplasms	Hellenic Society of Hematology	P1/2	CC (41)
gsk4524101 Neoplasms	GlaxoSmithKline	P1/2	CC (41)
gsk5460025 Neoplasms	GlaxoSmithKline	P1/2	CC (41)
htl0039732 capsules Neoplasms	Cancer Research UK	P1/2	CC (41)
IM19 CAR-T cells Neoplasms	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1/2	CC (41)
Nenocorilant Neoplasms	Corcept Therapeutics	P1/2	CC (41)
Sonovue Neoplasms	NaviFUS Corporation	P1/2	CC (41)
ty-1091 Neoplasms	TYK Medicines, Inc	P1/2	CC (41)
vb15010 Neoplasms	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	P1/2	CC (41)
Cetrelimab Neoplasms	Johnson & Johnson Enterprise Innovation Inc.	P1	CC (40)
Jnj-64619178 Neoplasms	Janssen Research & Development, LLC	P1	CC (40)
Jnj-70218902 Neoplasms	Janssen Research & Development, LLC	P1	CC (40)
Jnj-78306358 Neoplasms	Janssen Research & Development, LLC	P1	CC (40)
mk-4464 Neoplasms	Merck Sharp & Dohme LLC	P1	CC (40)
Tsr-033 Neoplasms	Tesaro, Inc.	P1	CC (40)
vip236 Neoplasms	Vincerx Pharma, Inc.	P1	CC (40)
Sasanlimab Neoplasms	Pfizer	P2	C (39)
plx038 Neoplasms	Institut Curie	P1	C (39)
5-AZA-T-DCYD Neoplasms	National Cancer Institute (NCI)	P1	C (37)

Showing 51 to 75 of 119 assets